Hongliang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongliang Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Bin Xiong
Department of Interventional Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
3 shared publications Baoquan Wang
Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
1 shared publicationChen Zhou
1 shared publication- Chencheng Wang
School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang 212013, Jiangsu Province, PR China
1 shared publication - Cheng Ding
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine
1 shared publication - Chenyang Huang
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
1 shared publication
Latest Publications
- 7 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Prognostic Value of Psoas Muscle Index Improvement in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt
- 7 August 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (11)
Prognostic Value of Psoas Muscle Index Improvement in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt
- Open Access
- 30 March 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31 (1) , 24-35
Clinical challenges and transjugular intrahepatic portosystemic shunt strategies for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: an Asian perspective
Pyrrolizidine alkaloid–induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is highly prevalent in Asia, primarily due to the widespread use of traditional herbal medicines containing hepatotoxic pyrrolizidine alkaloids. This condition poses significant clinical challenges, including diagnostic difficulties and limited therapeutic options, frequently leading to severe liver damage and portal hypertension. Transjugular intrahepatic portosystemic shunt (TIPS) treatment has emerged as a key intervention for managing complications associated with PA-HSOS, such as refractory ascites and variceal bleeding, by reducing portal pressure and supporting liver function recovery. However, TIPS has not been widely accepted as a salvage therapy for severe PA-HSOS unresponsive to anticoagulation therapy, mainly due to concerns about post-TIPS complications, particularly hepatic encephalopathy. Consequently, careful patient selection and risk stratification are critical. This review synthesizes the current evidence on PA-HSOS in Asia, evaluates the clinical utility of TIPS, and discusses strategies to optimize outcomes while minimizing adverse effects. Specifically, we review the epidemiology, pathophysiology, and diagnostic advancement of PA-HSOS, with a particular focus on the evolving role of TIPS in its management.
- 30 March 2026
- Published by Korean Society of Interventional Radiology in Korean Journal of Interventional Radiology
- Vol. 31 (1) , 24-35
Open AccessClinical challenges and transjugular intrahepatic portosystemic shunt strategies for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: an Asian perspective
Pyrrolizidine alkaloid–induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is highly prevalent in Asia, primarily due to the widespread use of traditional herbal medicines containing hepatotoxic pyrrolizidine alkaloids. This condition poses significant clinical challenges, including diagnostic difficulties and limited therapeutic options, frequently leading to severe liver damage and portal hypertension. Transjugular intrahepatic portosystemic shunt (TIPS) treatment has emerged as a key intervention for managing complications associated with PA-HSOS, such as refractory ascites and variceal bleeding, by reducing portal pressure and supporting liver function recovery. However, TIPS has not been widely accepted as a salvage therapy for severe PA-HSOS unresponsive to anticoagulation therapy, mainly due to concerns about post-TIPS complications, particularly hepatic encephalopathy. Consequently, careful patient selection and risk stratification are critical. This review synthesizes the current evidence on PA-HSOS in Asia, evaluates the clinical utility of TIPS, and discusses strategies to optimize outcomes while minimizing adverse effects. Specifically, we review the epidemiology, pathophysiology, and diagnostic advancement of PA-HSOS, with a particular focus on the evolving role of TIPS in its management.
- Open Access
- 30 November 2025
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 4 (4) , 275-277
Successful Embolization for Recurrent Encephalopathy Caused by Type II Abernethy Malformation
- 30 November 2025
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 4 (4) , 275-277
Open AccessSuccessful Embolization for Recurrent Encephalopathy Caused by Type II Abernethy Malformation
- 1 November 2019
- Published by Wiley in Liver International
- Vol. 40 (2) , 298-307
Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030
Background & Aims: Trends in long‐term mortality rates for viral hepatitis in East and Southeast Asia have been rarely reported. The aim of our study was to explore the long‐term trends in viral hepatitis mortality rates in East and Southeast Asian countries between 1987 and 2015 and provide predictions of mortality to 2030.Methods: We obtained viral hepatitis mortality data from the WHO Mortality Database for six East and Southeast Asian countries between 1987 and 2015. We produced choropleth maps of viral hepatitis mortality rates in 1987 and 2015 in East and Southeast Asia to illustrate geographic variations. We made predictions of mortality rates for each included country until the year 2030 using a series of joinpoint models.Results: Viral hepatitis mortality rates declined in China (the average annual percent change (AAPC) = −5.1%, 95% CI: −7.5, −2.6), Singapore (AAPC = −5.4%, 95% CI: −7.5, −3.2), and the Philippines (AAPC = −3.4%, 95% CI: −4.9, −1.8). In contrast, Japan, the Republic of Korea, and Malaysia have experienced increasing trends in mortality rates, followed by decreasing trends. Our predictions indicate that all countries will experience slight to moderate downward trends until 2030.Conclusion: Favourable decreasing trends have been noted in East and Southeast Asian countries, which may not only inform the control and management of viral hepatitis in this region but also guide the prevention of viral hepatitis deaths in another region with a similar viral hepatitis epidemic.
- 1 November 2019
- Published by Wiley in Liver International
- Vol. 40 (2) , 298-307
Changing trends in viral hepatitis mortality in East and Southeast Asia between 1987 and 2015 and its prediction until 2030
Background & Aims: Trends in long‐term mortality rates for viral hepatitis in East and Southeast Asia have been rarely reported. The aim of our study was to explore the long‐term trends in viral hepatitis mortality rates in East and Southeast Asian countries between 1987 and 2015 and provide predictions of mortality to 2030.Methods: We obtained viral hepatitis mortality data from the WHO Mortality Database for six East and Southeast Asian countries between 1987 and 2015. We produced choropleth maps of viral hepatitis mortality rates in 1987 and 2015 in East and Southeast Asia to illustrate geographic variations. We made predictions of mortality rates for each included country until the year 2030 using a series of joinpoint models.Results: Viral hepatitis mortality rates declined in China (the average annual percent change (AAPC) = −5.1%, 95% CI: −7.5, −2.6), Singapore (AAPC = −5.4%, 95% CI: −7.5, −3.2), and the Philippines (AAPC = −3.4%, 95% CI: −4.9, −1.8). In contrast, Japan, the Republic of Korea, and Malaysia have experienced increasing trends in mortality rates, followed by decreasing trends. Our predictions indicate that all countries will experience slight to moderate downward trends until 2030.Conclusion: Favourable decreasing trends have been noted in East and Southeast Asian countries, which may not only inform the control and management of viral hepatitis in this region but also guide the prevention of viral hepatitis deaths in another region with a similar viral hepatitis epidemic.